Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo

Phase 3positivezipalertinibPositive

AI Analysis

Summary

Taiho Oncology's Phase III REZILIENT3 trial evaluating zipalertinib in combination with chemotherapy demonstrated positive results, as discussed by the company's CMO Dr Harold Keer.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

REZILIENT3 trial of zipalertinib and chemotherapy combination showed positive data

Importance:7/10

Sentiment:

0.70

Phase 3oncologycombination therapyzipalertinibREZILIENT3

Related Companies

$DFPH $MDCE $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 7, 2026 11:52 AM

Read Original